Monoclonal Anti-CD52 Antibody, Human IgG1, Research Grade

Research use only

Features and Advantages

1. Native Conformation: Native sequences, tag-free and natural function.
2. Reliable Activity: Biological activity calibrated against WHO/NIBSC standards.
3. Stringent Quality Control: Protein content, purity, and cell-based bioactivity testing for each batch.
4. Lowest Endotoxin level (<0.01 EU/ug).
5. Safety Assurance: Sterile filtration through 0.2 μm membrane.
6. AOF: Animal origin-free raw materials throughout the production process.

Source

Monoclonal Anti-CD52 Antibody, Human IgG1, Research Grade (CD2-C263GN) is a recombinant humanized anti-CD52 monoclonal antibody, produced using the HEK293 expression system.

Isotype

Human IgG1 | Human Kappa

Specificity

This product is an antibody that specifically reacts with human CD52.

Endotoxin

Less than 0.01 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping

This product is supplied and shipped with dry ice, please inquire the shipping cost.

Storage

For long term storage, the product should be stored at liquid state at -70°C.

This product is stable after storage at:

1. -70°C for 24 months.

ACRO Quality Management System

1. QMS(ISO, GMP)
2. Quality Advantages
3. Quality Control Process

Quality Description

ACRO's Research-grade products are suitable for a wide range of cell culture applications, particularly for research use in academic institutions. These products are sterilized by filtration, followed by lyophilization where applicable. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. Biological activity is calibrated against WHO/NIBSC standards when available.
ACRO's Premium-grade (Pre-GMP) products are characterized by their high quality and enhanced safety profiles, making them ideal for early-stage discovery and manufacturing processes in cell therapy companies. A key advantage is their seamless transition to corresponding GMP-grade versions. Biological activity is calibrated against WHO/NIBSC standards when available. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. In addition, rigorous testing is conducted to ensure the absence of mycoplasma, HCD, and HCP, thereby guaranteeing product safety.